A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf
.
Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology
2021
Psychopharmacology
There is urgent need for new medications for psychiatric disorders. Mental illness is expected to become the leading cause of disability worldwide by 2030. Yet, the last two decades have seen the pharmaceutical industry withdraw from psychiatric drug discovery after costly late-stage trial failures in which clinical efficacy predicted pre-clinically has not materialised, leading to a crisis in confidence in preclinical psychopharmacology. Based on a review of the relevant literature, we
doi:10.1007/s00213-021-05787-x
pmid:33694032
fatcat:gh4m3mmjlzhirfh3ekenxpddvi